title: Plasmapheresis in cast nephropathy: yes or no?
abstract: OBJECTIVE
  Renal failure is a frequent complication of multiple myeloma and portends a poor prognosis. Plasmapheresis has been suggested as an adjunct to chemotherapy to halt or reverse renal injury associated with multiple myeloma. The purpose of this article is to review the rationale for using plasmapheresis for this indication and then provide a discussion of the evidence regarding its use.
  
  
  RESULTS
  The outcome of patients with multiple myeloma has improved considerably in recent years, mostly owing to the introduction of new highly effective chemotherapeutic agents. However, patients with renal failure who do not recover independent renal function continue to have very poor prognosis. Recent evidence now indicates that an early and sustained reduction in circulating free light chains (FLCs) is associated with improved renal recovery in patients with myeloma kidney. Extracorporeal removal of FLCs with plasmapheresis, or other techniques, can achieve rapid and sustained reduction in serum FLC concentration in patients with acute myeloma kidney. Unfortunately, there is currently no convincing evidence in the literature that the addition of mechanical removal of FLC to standard chemotherapy translates into clinical benefits for patients.
  
  
  CONCLUSIONS
  Plasmapheresis is theoretically attractive as a means of rapidly lowering serum FLC burden in the hope of reducing nephrotoxicity in patients with multiple myeloma. However, the role of plasmapheresis in improving renal prognosis and patient survival remains to be demonstrated.
authors.affiliation: Department of Nephrology, Hôpital du Sacré-Coeur de Montréal, Montréal, Québec, Canada.
authors.forename: François
authors.initials: F
authors.lastname: Madore
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000097:blood*; D007668:Kidney / Q000187:drug effects; D007674:Kidney Diseases / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D010956:Plasmapheresis / Q000379:methods; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents; D007147:Immunoglobulin Light Chains